NEW YORK, Aug. 13 (GenomeWeb News) -- Xerion Pharmaceuticals of Martinsried, Germany, announced today that it has licensed bacterial expression technology developed by Xoma Ireland.
In a statement, Xerion said it will have rights to use Xoma’s antibody expression technology for developing antibody products derived from phage display libraries for itself and its collaborators. The company also has an option to license the production of antibodies under Xoma patents. Xoma will receive license and royalty payments. The two companies also announced a co-development and commercialization option on antibody products generated by Xerion.
Further financial details were not provided.